Phenotypic Screening Using Large-scale Genomic Libraries to Identify Drug Targets for the Treatment of Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2020 May 12

PMID 32391087

Citations 4

Authors

Mitsuo Sato

Affiliations

Soon will be listed here.

Abstract

During malignant progression to overt cancer cells, normal cells accumulate multiple genetic and non-genetic changes, which result in the acquisition of various oncogenic properties, such as uncontrolled proliferation, drug resistance, invasiveness, anoikis-resistance, the ability to bypass oncogene-induced senescence and cancer stemness. To identify potential novel drug targets contributing to these malignant phenotypes, researchers have performed large-scale genomic screening using various and screening models and identified numerous promising cancer drug target genes. However, there are issues with these identified genes, such as low reproducibility between different datasets. In the present study, the recent advances in the functional screening for identification of cancer drug target genes are summarized, and current issues and future perspectives are discussed.

Citing Articles

Self-Renewal Inhibition in Breast Cancer Stem Cells: Moonlight Role of PEDF in Breast Cancer.

Gil-Gas C, Sanchez-Diez M, Honrubia-Gomez P, Sanchez-Sanchez J, Alvarez-Simon C, Sabater S Cancers (Basel). 2023; 15(22).

PMID: 38001682 PMC: 10670784. DOI: 10.3390/cancers15225422.

Hypothesis-generating proteome perturbation to identify NEU-4438 and acoziborole modes of action in the African Trypanosome.

Sharma A, Cipriano M, Ferrins L, Hajduk S, Mensa-Wilmot K iScience. 2022; 25(11):105302.

PMID: 36304107 PMC: 9593816. DOI: 10.1016/j.isci.2022.105302.

RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells.

Holzen L, Mitschke J, Schonichen C, Hess M, Ehrenfeld S, Boerries M Theranostics. 2022; 12(9):4348-4373.

PMID: 35673573 PMC: 9169373. DOI: 10.7150/thno.68299.

Generation of Protein Inhibitors for Validation of Cancer Drug Targets Identified in Functional Genomic Screens.

McDonald S, Annan Sudarsan A, Babeker H, Budharaju K, Uppalapati M Methods Mol Biol. 2021; 2381:307-331.

PMID: 34590284 DOI: 10.1007/978-1-0716-1740-3_17.

References

Yamanoi K, Matsumura N, Murphy S, Baba T, Abiko K, Hamanishi J . Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. Oncotarget. 2016; 7(30):47620-47636. PMC: 5216966. DOI: 10.18632/oncotarget.9951. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Whitehurst A, Bodemann B, Cardenas J, Ferguson D, Girard L, Peyton M . Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 2007; 446(7137):815-9. DOI: 10.1038/nature05697. View

Sato M, Shames D, Gazdar A, Minna J . A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007; 2(4):327-43. DOI: 10.1097/01.JTO.0000263718.69320.4c. View

Lin L, Chamberlain L, Pak M, Nagarajan A, Gupta R, Zhu L . A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signaling. Cancer Discov. 2014; 4(10):1168-81. PMC: 4184919. DOI: 10.1158/2159-8290.CD-13-0747. View

Paoli P, Giannoni E, Chiarugi P . Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013; 1833(12):3481-3498. DOI: 10.1016/j.bbamcr.2013.06.026. View

Maruyama Y, Miyazaki T, Ikeda K, Okumura T, Sato W, Horie-Inoue K . Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway. PLoS One. 2014; 9(10):e108743. PMC: 4186824. DOI: 10.1371/journal.pone.0108743. View

He S, Sharpless N . Senescence in Health and Disease. Cell. 2017; 169(6):1000-1011. PMC: 5643029. DOI: 10.1016/j.cell.2017.05.015. View

Seshadri R, Matthews C, Dobrovic A, Horsfall D . The significance of oncogene amplification in primary breast cancer. Int J Cancer. 1989; 43(2):270-2. DOI: 10.1002/ijc.2910430218. View

10.

Yilmaz M, Christofori G . EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28(1-2):15-33. DOI: 10.1007/s10555-008-9169-0. View

11.

Guerreiro A, Fattet S, Kulesza D, Atamer A, Elsing A, Shalaby T . A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res. 2011; 9(7):925-35. DOI: 10.1158/1541-7786.MCR-10-0200. View

12.

Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, Zuo Z . A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Res. 2017; 77(16):4402-4413. PMC: 5559306. DOI: 10.1158/0008-5472.CAN-16-1627. View

13.

ONeil N, Bailey M, Hieter P . Synthetic lethality and cancer. Nat Rev Genet. 2017; 18(10):613-623. DOI: 10.1038/nrg.2017.47. View

14.

Vogelstein B, Kinzler K . The multistep nature of cancer. Trends Genet. 1993; 9(4):138-41. DOI: 10.1016/0168-9525(93)90209-z. View

15.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

16.

Bartz S, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A . Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol. 2006; 26(24):9377-86. PMC: 1698535. DOI: 10.1128/MCB.01229-06. View

17.

Gray-Schopfer V, Cheong S, Chong H, Chow J, Moss T, Abdel-Malek Z . Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. Br J Cancer. 2006; 95(4):496-505. PMC: 2360676. DOI: 10.1038/sj.bjc.6603283. View

18.

Cheung H, Cowley G, Weir B, Boehm J, Rusin S, Scott J . Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011; 108(30):12372-7. PMC: 3145679. DOI: 10.1073/pnas.1109363108. View

19.

Jackson C, Choi J, Lim M . Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019; 20(9):1100-1109. DOI: 10.1038/s41590-019-0433-y. View

20.

Sudo M, Mori S, Madan V, Yang H, Leong G, Koeffler H . Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer. Oncotarget. 2014; 6(2):814-24. PMC: 4359257. DOI: 10.18632/oncotarget.2891. View